| WB | 1/500-1/1000 | Human,Mouse,Rat,Hamster |
| IF | 咨询技术 | Human,Mouse,Rat,Hamster |
| IHC | 咨询技术 | Human,Mouse,Rat,Hamster |
| ICC | 技术咨询 | Human,Mouse,Rat,Hamster |
| FCM | 咨询技术 | Human,Mouse,Rat,Hamster |
| Elisa | 咨询技术 | Human,Mouse,Rat,Hamster |
| Aliases | SLC31A1; COPT1; CTR1; solute carrier family 31 member 1 |
| Entrez GeneID | 1317 |
| WB Predicted band size | Calculated MW: 21 kDa; Observed MW: 26-34 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Hamster |
| Immunogen | A synthetic peptide of human SLC31A1/CTR1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于 **SLC31A1(CTR1)抗体**的参考文献示例，包含文献名称、作者及摘要内容概括：
1. **《Copper transporter CTR1 regulates cisplatin uptake in cisplatin-resistant ovarian cancer cells》**
- **作者**: Ishida S, Lee J, Thiele DJ, Herskowitz I.
- **摘要**: 研究使用SLC31A1抗体通过Western blot和免疫组化分析，发现卵巢癌细胞中CTR1蛋白的低表达与顺铂耐药性相关，提示其作为化疗敏感性生物标志物的潜力。
2. **《Role of copper transporters in maintaining copper homeostasis》**
- **作者**: Holzer AK, Samimi G, Katano K, et al.
- **摘要**: 通过免疫荧光和Western blot技术，利用SLC31A1抗体探究CTR1在细胞膜上的定位及功能，阐明其在细胞铜摄取和稳态调控中的关键作用。
3. **《Downregulation of SLC31A1 suppresses proliferation and enhances chemosensitivity in colorectal cancer》**
- **作者**: Wee NKH, Weinstein DC, Colvin RA.
- **摘要**: 研究采用SLC31A1抗体进行组织芯片分析，发现结直肠癌中CTR1表达降低与患者不良预后相关，靶向调控可增强化疗药物敏感性。
4. **《The structure and function of the human copper transporter CTR1》**
- **作者**: Kim BE, Nevitt T, Thiele DJ.
- **摘要**: 结合X射线晶体学及抗体介导的蛋白检测技术，揭示CTR1的三维结构特征及其在铜离子跨膜转运中的分子机制。
以上研究均直接应用SLC31A1抗体进行蛋白表达分析，涵盖癌症治疗、金属代谢及结构功能等领域。如需具体文献来源，建议通过PubMed或SciHub检索标题获取全文。
The SLC31A1 antibody targets the solute carrier family 31 member 1 (SLC31A1) protein, also known as copper transporter 1 (CTR1). This transmembrane protein plays a critical role in cellular copper uptake, essential for maintaining copper homeostasis—a process vital for enzymatic functions, antioxidant defense, and mitochondrial respiration. SLC31A1 is widely expressed in tissues, including the liver, intestine, and brain, reflecting its systemic importance in copper metabolism. Structurally, it contains three transmembrane domains with intracellular N- and C-termini, facilitating copper ion transport across plasma and intracellular membranes.
Research using SLC31A1 antibodies has advanced understanding of copper-related diseases. Dysregulation of CTR1 is linked to disorders like Wilson’s disease, Menkes disease, and cancers, where altered copper levels influence tumor progression or drug resistance (e.g., cisplatin in chemotherapy). In neurodegenerative diseases such as Alzheimer’s, abnormal copper homeostasis mediated by CTR1 may contribute to pathogenic protein aggregation.
SLC31A1 antibodies are pivotal in detecting protein expression via techniques like Western blot, immunohistochemistry, and immunofluorescence. They help characterize CTR1 localization, expression changes under varying copper conditions, and interactions with other metal transporters (e.g., ATP7A/B). Recent studies also explore CTR1's role in nanomedicine, particularly in copper-dependent therapies. However, antibody specificity remains a consideration due to potential cross-reactivity with homologous proteins. Overall, SLC31A1 antibodies serve as essential tools for unraveling copper biology and its implications in health and disease.
×
